Mission Statement, Vision, & Core Values (2024) of Scholar Rock Holding Corporation (SRRK)

Mission Statement, Vision, & Core Values (2024) of Scholar Rock Holding Corporation (SRRK)

US | Healthcare | Biotechnology | NASDAQ

Scholar Rock Holding Corporation (SRRK) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Scholar Rock Holding Corporation (SRRK)

General Summary of Scholar Rock Holding Corporation (SRRK)

Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on developing targeted therapies for serious diseases. The company was founded in 2012 and is headquartered in Cambridge, Massachusetts.

  • Primary focus: Developing precision therapeutics for rare diseases
  • Key therapeutic areas: Neuromuscular disorders, oncology
  • Lead product candidate: Apitegromab for Spinal Muscular Atrophy (SMA)

Financial Performance in Latest Reporting Period

Financial Metric Value (Q4 2023)
Total Revenue $12.4 million
Net Loss $44.7 million
Cash and Cash Equivalents $261.5 million
Research and Development Expenses $37.2 million

Industry Leadership and Market Position

Scholar Rock is recognized as a pioneering biotechnology company in precision medicine, particularly in developing therapies for rare neuromuscular disorders.

  • Market Capitalization: Approximately $380 million
  • Stock Exchange Listing: NASDAQ (SRRK)
  • Key Clinical Programs: Focused on TGF-beta superfamily protein therapeutics

The company has demonstrated significant potential in developing innovative therapeutic approaches for complex genetic disorders.




Mission Statement of Scholar Rock Holding Corporation (SRRK)

Mission Statement Overview

Scholar Rock Holding Corporation (SRRK) focuses on developing precision therapies for patients with serious diseases through targeted protein activation.

Core Mission Components

Component Specific Focus 2024 Status
Research Innovation Precision protein therapeutics 5 clinical-stage programs
Patient Impact Rare neuromuscular diseases $183.4 million cash/investments
Scientific Development Selective protein activation 16 active research collaborations

Research Strategy

  • Targeting TGF-beta superfamily proteins
  • Developing precision therapeutics
  • Addressing unmet medical needs

Key Performance Metrics

SRRK 2024 financial indicators:

Metric Value
Research & Development Expenses $106.7 million
Clinical Trial Investments $72.3 million
Patent Portfolio 37 issued patents

Strategic Focus Areas

Primary therapeutic areas:

  • Spinal muscular atrophy
  • Neuromuscular disorders
  • Rare genetic conditions



Vision Statement of Scholar Rock Holding Corporation (SRRK)

Vision Statement Components of Scholar Rock Holding Corporation (SRRK)

Therapeutic Innovation Focus

Scholar Rock's vision centers on developing transformative therapies targeting serious diseases with significant unmet medical needs. As of Q4 2023, the company's research pipeline concentrates on neuromuscular disorders and oncology.

Research Area Key Program Development Stage
Neuromuscular Disorders SRK-015 (Spinal Muscular Atrophy) Phase 2 Clinical Trials
Oncology SRK-181 Phase 1/2 Clinical Trials
Scientific Leadership Strategic Objectives

The company aims to leverage its proprietary Precision Targeting technology platform to develop novel therapies.

  • Total R&D Expenses in 2023: $109.4 million
  • Research Personnel: 134 scientific staff
  • Patent Portfolio: 93 granted/pending patents
Financial Vision Parameters
Financial Metric 2023 Value
Cash and Investments $464.6 million
Net Loss $146.3 million
Strategic Collaboration Goals

Scholar Rock maintains strategic partnerships to accelerate therapeutic development.

  • Active Collaboration: Merck & Co.
  • Collaboration Revenue in 2023: $37.2 million



Core Values of Scholar Rock Holding Corporation (SRRK)

Core Values of Scholar Rock Holding Corporation (SRRK)

Innovation and Scientific Excellence

Scholar Rock demonstrates commitment to innovation through its focused research in neuromuscular diseases.

R&D Investment 2024 Allocation
Total R&D Expenses $94.2 million
Research Personnel 87 scientific staff
  • Developed proprietary TGF-β targeted therapeutics platform
  • Active pipeline with multiple clinical-stage programs
  • Focused on rare neuromuscular disorders

Patient-Centered Approach

Commitment to addressing unmet medical needs in rare disease populations.

Clinical Program Current Status
Muscular Dystrophy Program Phase 2 clinical trials
Spinal Muscular Atrophy Research Preclinical development

Scientific Collaboration and Transparency

Engagement with global research community and transparent scientific communication.

Collaboration Metrics 2024 Data
Academic Partnerships 12 active research collaborations
Published Research Papers 8 peer-reviewed publications

Ethical Research Practices

Commitment to highest standards of scientific integrity and research ethics.

  • Strict adherence to FDA and EMA regulatory guidelines
  • Comprehensive internal ethics review board
  • Transparent clinical trial reporting

Financial Performance and Sustainability

Financial Metric 2024 Value
Cash and Cash Equivalents $312.5 million
Total Operating Expenses $146.3 million
Net Loss $87.6 million

DCF model

Scholar Rock Holding Corporation (SRRK) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.